Arthurian Life Sciences

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Rutherford Health is a UK-based company that specializes in providing comprehensive cancer care services through its network of Rutherford Cancer Centres. Founded in 2015 and previously known as Proton Partners International Limited, the company offers a variety of treatments including proton beam therapy, radiotherapy, chemotherapy, immunotherapy, and hormone therapy, alongside diagnostic services like computerized tomography and magnetic resonance imaging. Rutherford Health caters to private patients with medical insurance, self-paying individuals, and those referred by the National Health Service. In addition to its treatment offerings, the company is involved in development and infrastructure activities to enhance its service delivery. Rutherford Health has established a strategic collaboration with Panthera Biopartners to further advance its cancer care capabilities.

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Sphere Medical Holding plc, established in 2001 and headquartered in Cardiff, UK, specializes in developing and selling medical monitoring and diagnostic equipment. The company's primary product, the Proxima solution, measures blood gases, electrolytes, and metabolites, aiding in the care of critically ill and unstable patients. Sphere Medical's innovative products, including microanalyser platforms and various monitoring systems, provide healthcare professionals with crucial data to manage therapy and optimize patient outcomes. The company operates in the UK, Europe, and Japan, and its products are designed to deliver both clinical and economic benefits.

Interrad Medical is a medical device company located in Plymouth, Minnesota. The company was founded by Dr. Michael Rosenberg, a practicing interventional radiologist, in collaboration with several other highly regarded physicians. The company's mission is the development and commercialization of innovative medical devices for use in minimally invasive interventional and surgical procedures. Interrad Medical has an experienced market-proven team with a successful track record of bringing devices through development to commercialization. it has a robust product portfolio targeting minimally invasive vascular and surgical procedures. These devices are designed to solve unmet medical needs and serve large, growing patient populations.

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

ReNeuron Group is a biotechnology company based in Pencoed, United Kingdom, specializing in the research and development of cell-based therapies for various medical conditions. Founded in 1997, it is primarily focused on developing innovative treatments for stroke disability and inherited retinal diseases, including its CTX stem cell therapy candidate, which is currently undergoing Phase IIb clinical trials, and its human retinal progenitor cell therapy, which is in Phase I/IIa trials for retinitis pigmentosa. The company is also exploring the therapeutic potential of CTX-derived exosomes, which are nano-sized packages of information released by CTX cells. Additionally, ReNeuron has established a research agreement with a U.S. biotechnology firm to collaborate on novel gene silencing-based therapeutics. Through its advanced product pipeline and strategic partnerships, ReNeuron aims to address significant unmet medical needs in the therapeutic landscape.